SLC5A2 and type 2 diabetes mellitus: ntrolled trial was conducted to investigate the preventive effects of tofogliflozin, an SGLT2 inhibitor, on the progression of carotid intima-media thickness (IMT) in patients with apparent CVD-free T2DM, and found that there were no significant differences in the progression of IMT between the tofogliflozin treatment and conventional treatment [6].